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The high-prevalence antigen, Ata, was first identified in 1967, but 
it was not until 2015 that Ata became AUG1 of a new blood group 
system, Augustine (AUG). The new system was established after 
the identification of the gene encoding Ata and the recognition of a 
null phenotype (AUG:–1,–2) in an At(a–) patient with an antibody 
(anti-AUG2) reactive with At(a–) red blood cells. The At(a–) 
phenotype is very rare and, with the exception of the one family with 
the null phenotype, has only been found in individuals of African 
origin. Anti-Ata has been implicated in immediate and delayed 
hemolytic transfusion reactions, but not in severe hemolytic 
disease of the fetus and newborn. The Augustine gene is SLC29A1, 
which encodes the equilibrative nucleoside transporter ENT1. 
At(a–) (AUG:–1,2) results from homozygosity for c.1171G>A, 
encoding Glu391Lys, whereas the AUGnull (AUG:–1,–2) phenotype 
results from homozygosity for a splice site mutation, c.589+1G>C, 
in the only family where it has been found. Absence of ENT1 in 
that family may be associated with pseudogout and abnormal 
bone calcification. Immunohematology 2016;32:100–103.
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In 1967, Applewhaite et al.1 described the first example of 
anti-Ata, an antibody to a common antigen. Six more examples 
were reported in 1973,2 and an antigen, originally reported3 
as El, was subsequently shown to be of the same specificity.4 
Ata was numbered 901003, as part of the 901 series of high-
prevalence antigens, until 2015, when Daniels et al.5 identified 
the gene encoding Ata as SLC29A1, and thus, a new blood group 
system containing Ata (AUG1) and a new antigen, AUG2, was 
established.6 Augustine (AUG) became the 36th blood group 
system (Table 1).
Ata (AUG1) and Anti-Ata
Ata is a common antigen. All reported At(a–) individuals 
have been of African origin, and in several surveys, only 1 
of about 16,450 African Americans was At(a–).1,3,7,8 Family 
analyses provided strong evidence that the At(a–) phenotype 
results from homozygosity for a recessive gene.1–3,9–11 Ata is 
not destroyed by treatment of At(a+) red blood cells (RBCs) 
with trypsin, α-chymotrypsin, papain, pronase, sialidase, 
200 mmol/L dithiothreitol, or 2-aminoethylthiouronium 
bromide and is expressed strongly on cord RBCs.12,13
Anti-Ata may be stimulated by transfusion or pregnancy; 
no example of “naturally occurring” anti-Ata is known. Ata 
antibodies are mostly immunoglobulin G (IgG), reacting by 
an antiglobulin test, although one serum also contained some 
directly agglutinating IgM.2 IgG anti-Ata was subtyped in two 
sera: one contained IgG1; the other contained IgG1, IgG3, and 
IgG4.14
AUG2 and Anti-AUG2
In 1994, an antibody in an At(a−) pregnant woman with 
consanguineous parents (Fig. 1) reacted with all RBCs tested, 
with the exception of those of her two At(a−) siblings. The 
positively reacting RBCs included RBCs of many phenotypes 
lacking high-prevalence antigens that were available in 
several international reference laboratories. Furthermore, 
several examples of At(a−) RBCs reacted with the serum, 
demonstrating that the antibody was not anti-Ata. At that time, 
it was speculated that the patient may have a null phenotype 
(Daniels G, unpublished 1994). This speculation was confirmed 
21 years later by molecular genetics5 (see “Molecular Genetics 
of the Augustine Blood Group System” later in this review), 
and the antibody was named anti-AUG2.6
Anti-AUG2 reacted with RBCs treated with papain, 
trypsin, chymotrypsin, pronase, sialidase, or 2-aminoethyl-
thiouronium bromide (Daniels G, unpublished 1994).
Table 1. Antigens of the Augustine system and their molecular 
backgrounds
Antigens Molecular basis (SLC29A1)*
Name ISBT number Nucleotides Exon/intron Amino acids
Ata AUG1 036001 c.1171G (A) Exon 12 Glu391 (Lys)
– AUG2 036002 c.589+1G (C) Intron 6 Splice site mutation
*Molecular basis of antigen-negative phenotype provided in parentheses.
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Clinical Significance of Augustine Antibodies
There are two reports of hemolytic transfusion reactions 
(HTRs) caused by anti-Ata: one was an immediate HTR with 
chills and nausea during a RBC survival study;10 the other 
was a severe delayed HTR after transfusion of multiple units 
of At(a+) RBCs.11 Ata antibodies facilitate rapid destruction of 
51Cr-labelled At(a+) RBCs in vivo and give positive results in 
in vitro functional assays.9–10,14 Ideally, At(a−) RBC units 
should be selected for transfusion to patients with anti-Ata, 
although obtaining these units may not always be possible.
Despite numerous pregnancies involving anti-Ata, there 
has been no report of severe hemolytic disease of the fetus and 
newborn (HDFN). One case is described in which mild HDFN 
was treated with phototherapy.15 In a case of twins whose 
RBCs gave a 3+ direct antiglobulin reaction, molecular testing 
was applied as an aid to antibody identification.16 
The only known example of anti-AUG2 was probably 
responsible for a positive direct antiglobulin test on neonatal 
RBCs, but there was no evidence of HDFN.
Molecular Genetics of the Augustine Blood Group 
System
In 2015, the antibody, now called anti-AUG2, was used to 
purify a RBC membrane protein by immunoprecipitation and 
polyacrylamide gel electrophoresesis.5 Three tryptic peptides 
were analyzed by mass spectrometry, and their sequences 
were identified as being encoded by SLC29A1, the gene for the 
equilibrative nucleoside transporter 1 (ENT1, or solute carrier 
29A1).
Sequencing of SLC29A1 of five At(a–) individuals showed 
that they were all homozygous for c.1171G>A in exon 12 
(Table 1), encoding Glu391Lys in the fifth extracellular loop 
of ENT1 (Fig. 2).5 Homozygosity for this nucleotide change 
was also found in DNA isolated from eight samples of serum 
containing anti-Ata, including that of the original At(a–) 
propositus, Mrs. Augustine. The c.1171G>A transition in 
SLC29A1 corresponds to the minor (A) allele of rs4548701, 
which has only been detected in people of African ancestry. 
The U.S. National Institutes of Health Heart, Lung, and 
Blood Institute–sponsored Exome Sequencing Project found 
49 heterozygotes in 2203 African Americans, suggesting 
Augustine blood group system
Fig. 2 Diagrammatic representation of the conformation of 
equilibrative nucleoside transporter (ENT1) in the red blood cell 
membrane, with 11 membrane-spanning domains, internal amino 
terminal domain (N), and external carboxy-terminal domain (C), and 







Fig. 1 Pedigree of AUGnull propositus (arrow), showing Augustine 
phenotype and SLC29A1 intron 6 +1 genotype. Shaded squares 
and circles represent heterozygosity for the null allele; black squares 
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a frequency of about 1 percent for the rare allele, but none 
were found in 4300 European Americans,5 From the allele 
frequency, we can predict that the At(a–) phenotype would be 
present in about 1 in 10,000 African Americans. The A allele 
of rs4548701 creates the absence of a Taqα1 restriction site. 
Screening for rs4548701 A allele homozygosity could be used 
to search for At(a−) blood donors. No antibody specific for 
ENT1 with Lys391, which would represent anti-Atb, has been 
found.
Sequencing of SLC29A1 of the patient who had produced 
anti-AUG2 and who was suspected of having the AUGnull 
phenotype revealed that she was homozygous for a G-to-C 
transversion at the +1 position of intron 6 (c.589+1G>C) 
(Table 1), a splice-site mutation that was absent from the 
DNA of controls and in public databases. Her two AUG:–1,–2 
siblings were also homozygous for the mutation, and her 
consanguineous parents (Fig. 1), who were first cousins 
once removed, were both heterozygous for the mutation. 
Furthermore, immunoblotting revealed no ENT1 protein in the 
RBC membranes of the propositus.5 This testing confirmed 
that the patient does indeed have a null phenotype and that 
her antibody, now called anti-AUG2, is an antibody equivalent 
to anti-Ku, -JK3, -FY3, and -IFC of other blood group systems.
SLC29A1 and Its Product, ENT1
SLC29A1, the gene encoding the nucleoside transporter 
ENT1, was initially isolated from a human placental DNA 
library in 1997.15 The gene is located on chromosome 6p21.1 
and is organized into 13 exons.
ENT1, a member of the equilibrative or bidirectional 
family of nucleoside transporters, is a 456–amino acid 
glycoprotein that spans the membrane 11 times and has a 
cytosolic N-terminal domain and an external C-terminal 
domain (Fig. 2).17 ENT1, which is almost ubiquitously 
distributed in human tissues, facilitates the transfer of both 
purine and pyrimidine nucleosides, and is responsible for the 
majority of adenosine transport across the plasma membrane.18 
Although mice lacking ENT1 have been bred,19 the AUG:–1,–2 
propositus and her siblings were the first ENT1-deficient 
humans found.5
Because the AUG:–2 phenotype arises from homozygosity 
for an inactivating mutation in SLC29A1, it can be surmised 
that the AUG:–2 propositus and her siblings are deficient in 
ENT1 from all tissues, and some resultant morbidity might 
be expected. When these individuals were studied, at the 
ages of 45–50 years, they had no obvious developmental 
abnormalities, and they all had normal lifestyles.5 Nevertheless, 
all had suffered frequent attacks of pseudogout, a form of 
arthritis, since the age of 18–20 years. In addition, X-ray 
analysis revealed multiple calcifications around their hand 
joints and, in the propositus, ectopic calcification in the hips, 
pubic symphysis, and lumbar discs.5 We cannot confirm that 
ENT1 deficiency is responsible for these symptoms from the 
study of only one family, but adenine transport does appear to 
be an important factor in the regulation of bone metabolism,20 
and recent information obtained from Slc29a1–/– (“knockout”) 
mice supports this premise.21,22
ENT1 plays an important role in cellular uptake of 
nucleoside analog drugs, such as ribavirin, which is often used 
as front-line treatment of hepatitis C virus infection.23,24 The 
efficacy of such drugs could be compromised in patients with 
the extremely rare AUGnull phenotype.
SLC29A1 is highly expressed in early erythroid progenitor 
cells,5 and ENT1 is abundant in the membranes of mature 
RBCs.17 However, the biological importance of ENT1 in RBC 
function or in erythropoiesis remains to be resolved in light of 
the absence of any obvious erythroid abnormality associated 
with the AUGnull phenotype.
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